E-LIB Suche - Ergebnisse für: Nishio, Makoto

1

Optimal Treatment Strategy for Oligo-Recurrence Lung Cancer..:

Tachibana, Taimei ; Matsuura, Yosuke ; Ninomiya, Hironori...
Cancers. 16 (2024) 2 - p. 464 , 2024

2

Long-Term Efficacy and Safety of Lorlatinib in Japanese Pat..:

Teraoka, Shunsuke ; Hayashi, Hidetoshi ; Goto, Yasushi...
JTO Clinical and Research Reports. 5 (2024) 3 - p. 100632 , 2024

Link: https://doi.org/10.1016/..

3

Neuroendocrine and squamous cell phenotypes of NUT carcinom..:

Ninomiya, Hironori ; Sato, Yukiko ; Inamura, Kentaro...
Diagnostic Pathology. 19 (2024) 1 - p. , 2024

Link: https://doi.org/10.1186/..

4

Prediction of Tumor PD-L1 Expression in Resectable Non-Smal..:

Hashimoto, Kohei ; Murakami, Yu ; Omura, Kenshiro...
Clinical Lung Cancer. 25 (2024) 1 - p. e26-e34.e6 , 2024

Link: https://doi.org/10.1016/..

5

Efficacy of osimertinib in patients with EGFR‐mutation posi..:

Kiritani, Ayu ; Amino, Yoshiaki ; Uchibori, Ken...
Thoracic Cancer. , 2024

Link: https://doi.org/10.1111/..

6

Real-World Pharmacokinetics, Effectiveness, and Safety of A..:

Yagishita, Shigehiro ; Goto, Yasushi ; Nishio, Makoto...
JTO Clinical and Research Reports. , 2024

Link: https://doi.org/10.1016/..

7

Phase II Study of the Liposomal Formulation of Eribulin (E7..:

Nishio, Makoto ; Murakami, Shuji ; Kawakami, Hisato...
Cancer Research Communications. 4 (2024) 1 - p. 226-235 , 2024

Link: https://doi.org/10.1158/..

8

A macrocyclic kinase inhibitor overcomes triple resistant m..:

Suzuki, Mai ; Uchibori, Ken ; Oh-hara, Tomoko...
npj Precision Oncology. 8 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

9

KEYNOTE-434 part B: A phase 1 study evaluating the combinat..:

Yamamoto, Noboru ; Satouchi, Miyako ; Doi, Toshihiko...
Investigational New Drugs. 42 (2024) 3 - p. 261-271 , 2024

Link: https://doi.org/10.1007/..

10

HERTHENA-Lung02: phase III study of patritumab deruxtecan i..:

Mok, Tony ; Jänne, Pasi A ; Nishio, Makoto...
Future Oncology. 20 (2024) 15 - p. 969-980 , 2024

Link: https://doi.org/10.2217/..

11

Phase 1 study of pembrolizumab plus chemotherapy in Japanes..:

Nogami, Naoyuki ; Tokito, Takaaki ; Zenke, Yoshitaka...
Investigational New Drugs. 42 (2024) 1 - p. 136-144 , 2024

Link: https://doi.org/10.1007/..

12

Distinction of ALK fusion gene‐ and EGFR mutation‐positive ..:

Akita, Takahiro ; Ariyasu, Ryo ; Kakuto, Sho...
Thoracic Cancer. 15 (2024) 10 - p. 788-796 , 2024

Link: https://doi.org/10.1111/..

13

Real-World Data About Treatment Outcomes for Patients with ..:

Hayashi, Hidetoshi ; Nishio, Makoto ; Takahashi, Michiko..
Advances in Therapy. 40 (2023) 10 - p. 4545-4560 , 2023

Link: https://doi.org/10.1007/..

14

Soluble interleukin-2 receptor as a predictive biomarker fo..:

Tozuka, Takehiro ; Yanagitani, Noriko ; Yoshida, Hiroshi...
Investigational New Drugs. 41 (2023) 3 - p. 411-420 , 2023

Link: https://doi.org/10.1007/..

15

RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Me..:

Nishio, Makoto ; Paz-Ares, Luis ; Reck, Martin...
Clinical Lung Cancer. 24 (2023) 5 - p. 415-428 , 2023

Link: https://doi.org/10.1016/..